Answers are grounded in this paper and cite their sources.
Shows reduced treated rejection risk in intra-aortic balloon pump patients, indicating a potential benefit of recent policy changes.
Whether the increased use of temporary mechanical circulatory support (tMCS) as a bridge to heart transplantation following the 2018 UNOS policy change has translated to a different risk of treated rejection episodes is unknown. We included adult heart transplant recipients listed and transplanted between November 1, 2010 to October 31, 2020 from the UNOS registry.Multinomial logistic regression analysis was performed to determine the odds of post-transplant treated rejection compared to the non-MCS cohort. A total of 22,634 patients were stratified by tMCS type [intra-aortic balloon pump, percutaneous device, extracorporeal membrane oxygenation, and surgically implanted dischargeable or non-dischargeable ventricular assist devices]. Odds were higher for treated rejection relative to being alive and untreated for rejection for the IABP cohort compared to the non-MCS cohort in the pre era [OR: 1.47 (1.25, 1.72); p<0.001]. However, there was no difference in the odds of treated rejection [OR: 1.05 (0.85, 1.28); p=0.66] for IABP versus non-MCS patients in the post era. For other bridge-to-transplant therapies compared to the non-MCS cohort, the odds for treated rejection were not different based on policy era or tMCS sub-type. The policy change was associated with an attenuated risk of treated rejection amongst IABP-bridged recipients compared to the non-MCS cohort.
No takes yet. Share an insight, caveat, or question.
Vaidya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: